Pretreatment Eosinophil related ratios for assessing prognosis in Endometrial cancer - A Observational study

Not Applicable

• Conditions: Health Condition 1: C541- Malignant neoplasm of endometrium

• Registration Number: CTRI/2023/03/050646
• Lead Sponsor: DrAparajita

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

â??Women of any age group with proven Endometrial cancer who had undergone primary treatment

Exclusion Criteria

1.Inability to give informed consent

2.Pregnant women

3.Other concomitant Medical conditions like acute or chronic infections, including HIV, any immunodeficiency disorders/ Inflammatory disorders/ on drugs like steroids or anti - inflammatory treatment/ haematological disorders that may affect the blood cell counts.

4.Suspected / Diagnosed with Other Gynaecological malignancy (other than Endometrial cancer) and non gyanecological malignancies.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To assess the association between Eosinophilic ratios (ELR, ENLR) <br/ ><br>with Clinical, Surgical and Pathological characteristics in patients with endometrial cancer. <br/ ><br>2. To assess the association between Eosinophilic ratios (ELR, ENLR) <br/ ><br>with Recurrence free survival in patients with endometrial cancer. <br/ ><br>Timepoint: 1.To assess the association between Eosinophilic ratios (ELR, ENLR) <br/ ><br>with Clinical, Surgical and Pathological characteristics in patients with endometrial cancer after surgical management. <br/ ><br>2. To assess the association between Eosinophilic ratios (ELR, ENLR) <br/ ><br>with Recurrence free survival in patients with endometrial cancer after 6 months. <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
To assess the association between Eosinophilic ratios with <br/ ><br>1.Intraoperative and Postoperative adverse events <br/ ><br>2.Tumour histology <br/ ><br>Timepoint: JANUARY 2019 TO DECEMBER 2023